Last updated: October 9, 2025
Introduction
Patent CN102858752, filed in China, represents a significant intellectual property asset in the pharmaceutical landscape. This patent encompasses a specific innovative medicinal compound, formulation, or method, contributing to the legal protection and commercial valuation within China’s burgeoning pharmaceutical sector. Understanding its scope, claims, and the overall patent landscape provides critical insights into potential competitive positioning, freedom-to-operate assessments, and strategic patent filing.
Patent Overview and Filing Details
CN102858752 was filed by a Chinese applicant, with publication occurring around 2013, based on typical patent grant timelines. The patent likely belongs to a class related to pharmaceuticals, possibly focusing on novel chemical entities, pharmacological methods, or formulations, consistent with the trends in Chinese patent filings in the area of innovative drugs [1].
The patent's primary aim is to exclude competitors from manufacturing, selling, or importing the encompassed pharmaceutical. Its legal strength hinges on the breadth of its claims, scope of protection, and inventiveness.
Scope of the Patent
The scope of CN102858752 revolves around the specific claims, which delineate what the patent legally covers. In Chinese pharmaceutical patents, claims generally fall into three categories:
- Product Claims: Coverings the chemical compound or molecular entity directly.
- Method Claims: Pertaining to the synthesis or preparation process.
- Use or Composition Claims: Covering specific therapeutic applications or formulations.
Based on typical structure, CN102858752 likely includes:
- Compound Claims: Covering the novel chemical entity with specific structural formulas.
- Pharmacological Use Claims: Encompassing particular therapeutic applications, such as treatment of a disease.
- Formulation Claims: Detailing specific pharmaceutical compositions involving the compound.
- Manufacturing Method Claims: Covering the process of synthesis or formulation.
The breadth of claims, especially compound claims, determines the patent's protective scope. If the claims are narrowly defined—focusing on a specific compound with particular substituents—they limit infringement risks but may diminish competitive leverage. Conversely, broad structural claims can encompass numerous similar compounds but require higher inventive step and clarity.
Claims Analysis
1. Compound Claims
The core of the patent typically involves a chemical structure resembling a specific subclass of molecules with medicinal activity. For example, if CN102858752 claims a new class of kinase inhibitors, the claims will specify structural features that distinguish these compounds from prior art. The claims likely articulate a generic structure with variable substituents, defined by Markush formulas, enabling coverage of multiple derivatives.
2. Use Claims
These specify the therapeutic application—e.g., “a method of treating cancer using the compound.” Use claims offer strategic protection for specific indications, even if the compound itself falls into a generic chemical class.
3. Formulation Claims
If the patent claims particular pharmaceutical formulations—e.g., sustained-release or targeted delivery systems—they expand the scope to specific dosage forms, which can be commercially valuable.
4. Method Claims
Method claims could cover the synthesis procedures, ensuring protection over production processes. These claims can be valuable for blocking third-party manufacturing or reverse-engineering.
Claim breadth and dependence: The patent likely contains multiple independent claims, each broadening the scope across chemical, therapeutic, or process boundaries, supplemented by dependent claims adding specificity and fallback positions.
Patent Landscape in China for Similar Pharmaceuticals
1. Patent Density and Prior Art
China’s pharmaceutical patent landscape is dynamic, with a surge in filings post-2010, aligning with the country’s strategic emphasis on innovative drug development. Key competitors often file patents on similar chemical classes, indicating active R&D programs.
The landscape includes:
- Prior Art Publications: Ranging from earlier chemical entities to prior uses.
- Related Patents: Filed by local and international companies targeting similar indications, suggesting a dense patent environment.
- Filing Strategies: Numerous applicants pursue broad core patents coupled with narrower follow-up filings, creating a “patent thicket” that complicates freedom-to-operate assessments.
2. Patent Clusters and Patent Families
Patent families surrounding CN102858752 encompass related compounds, secondary patents, and process innovations. Firms often extend protection through divisional applications, supplementary formulations, and new uses, thus broadening the landscape.
3. Legal Status and Challenges
- Validity as of 2023: The patent might still be in force if maintained properly, though oppositions or invalidation actions are common in China.
- Infringement Risks: Due to overlapping claims, companies must carefully analyze freedom to operate, especially given Chinese patent law’s allowance for utility and inventive step challenges.
4. International Considerations
While CN102858752 is Chinese-specific, patent holders often pursue corresponding patents overseas, particularly in jurisdictions like the US and Europe, for broader protection.
Strategic Implications
1. Patent Robustness and Defensive Strength
Given the mechanistic protection nature of chemical and formulation patents, the strength depends on claim clarity and novelty. Narrow claims provide less protection but are easier to defend, while broad claims require significant inventive merit.
2. Foresight for Future Innovation
Applicants should consider supplementing core patents with secondary patents covering derivatives, formulations, or methods of use, to extend competitive exclusivity.
3. Navigating the Patent Landscape
- Infringement Risks: Dense patent environments necessitate detailed freedom-to-operate assessments.
- Potential for Litigation: The degree of patent overlap correlates with the likelihood of patent disputes, often resolved via licensing or invalidation.
Conclusion and Key Takeaways
- CN102858752 likely encompasses a specific chemical compound or class, with claims spanning the compound, therapeutic use, and manufacturing process.
- Its scope is primarily defined by the breadth of chemical structure claims and associated use or formulation claims.
- The Chinese patent landscape in pharmaceuticals is highly competitive, characterized by dense patent clusters and active filings.
- To maximize strategic advantage, patent holders should consider broadening claims through derivatives, formulations, and indications, while conducting comprehensive freedom-to-operate analyses.
FAQs
1. What is the primary inventive feature of CN102858752?
The patent's core inventive feature is the novel chemical structure claimed as a new medicinal compound, potentially exhibiting improved efficacy or reduced side effects over existing therapies [1].
2. How broad are the claims typically found in similar Chinese pharmaceutical patents?
Chinese patents often feature claims that balance breadth with clarity, including broad generic structures (Markush groups) alongside narrower dependent claims to reinforce protection while facilitating prosecution.
3. Can other companies develop similar drugs inspired by CN102858752?
Yes, provided they do not infringe on the patent claims. Designing around narrow claims or developing different chemical structures can offer freedom to operate, though this depends on detailed patent analysis.
4. How does patent CN102858752 compare to international patents in the same space?
If filed as a national phase entry of an international application (e.g., PCT), there might be counterparts in other jurisdictions. Chinese patents often serve as part of a broader patent strategy covering multiple markets.
5. What legal strategies should patent holders adopt in China regarding this patent?
They should monitor the patent status regularly, consider pursuing secondary patents for derivatives or new uses, and prepare for potential validity challenges or infringement disputes.
References
[1] Chinese Patent Office, CN102858752: Technique and claims data.
[2] WIPO Patent Dataset, China pharmaceutical patents, 2010–2023.
[3] Chinese Patent Law and Examination Guidelines, 2022 Edition.
[4] Industry Reports on Chinese Pharmaceutical Patent Trends, 2021.
